Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 36

1.

Multidimensional challenges in clinical drug development, regulatory approval, and marketing.

Ocana A, Seruga B, Amir E.

J Clin Oncol. 2013 Mar 20;31(9):1252-3. doi: 10.1200/JCO.2012.47.5699. Epub 2013 Feb 11. No abstract available.

2.

Making genuine progress against metastatic breast cancer.

Lyman GH, Burstein HJ, Buzdar AU, D'Agostino R, Ellis PA.

J Clin Oncol. 2012 Oct 1;30(28):3448-51. Epub 2012 Aug 27. Review. No abstract available.

PMID:
22927527
3.

Reply to A. Ocana et al.

Cortés J, Llombart-Cussac A, Calvo E.

J Clin Oncol. 2013 Mar 20;31(9):1253-4. No abstract available.

4.

Progress against solid tumors in danger: the metastatic breast cancer example.

Cortés J, Calvo E, González-Martín A, Dawood S, Llombart-Cussac A, De Mattos-Arruda L, Gómez P, Silva O, Perez EA, Rugo HS, Lluch A, Hortobagyi GN.

J Clin Oncol. 2012 Oct 1;30(28):3444-7. Epub 2012 Aug 27. No abstract available.

5.

FDA cancels approval for bevacizumab in advanced breast cancer.

Tanne JH.

BMJ. 2011 Nov 25;343:d7684. doi: 10.1136/bmj.d7684. No abstract available.

PMID:
22121166
6.

Avastin withdrawal symptoms.

Lynce F, Swain SM.

Expert Opin Pharmacother. 2012 Feb;13(3):293-8. doi: 10.1517/14656566.2012.652088. Epub 2012 Jan 21. No abstract available.

PMID:
22263961
7.

Pushing the envelope.

[No authors listed]

Nat Biotechnol. 2011 Aug 5;29(8):669. doi: 10.1038/nbt.1956. No abstract available.

PMID:
21822220
8.

FDA panel votes to pull Avastin in breast cancer, again.

Ratner M.

Nat Biotechnol. 2011 Aug 5;29(8):676. doi: 10.1038/nbt0811-676c. No abstract available. Erratum in: Nat Biotechnol. 2012 Feb;30(2):193.

PMID:
21822226
9.

Is the battle over bevacizumab coverage looming?

Larkin C.

J Natl Compr Canc Netw. 2011 Mar;9(3):261-3. No abstract available.

PMID:
21393437
10.

Bevacizumab recommendation highlights difficulties.

Printz C.

Cancer. 2011 Nov 15;117(22):5025. doi: 10.1002/cncr.26642. No abstract available.

11.

[Anti-angiogenic therapy for breast cancer--problems and future directions].

Sawaki M, Iwata H.

Nihon Rinsho. 2012 Sep;70 Suppl 7:614-9. Japanese. No abstract available.

PMID:
23350473
12.

Breast cancer: Neoadjuvant bevacizumab treatment-signal or noise?

Burstein HJ.

Nat Rev Clin Oncol. 2012 Mar 13;9(4):191-2. doi: 10.1038/nrclinonc.2012.34. No abstract available.

PMID:
22411347
13.

Avastin for breast cancer, 2005-2011: requiescat in pacem?

Burstein HJ.

J Natl Compr Canc Netw. 2011 Dec;9(12):1321-3. No abstract available.

PMID:
22157551
14.

Weighed, measured, and still searching: bevacizumab in the treatment of unselected patients with advanced breast cancer.

Lopes G, Dent R.

Oncologist. 2011;16(12):1669-71. doi: 10.1634/theoncologist.2011-0403. Epub 2011 Dec 8. No abstract available.

15.

Changing end points in breast-cancer drug approval--the Avastin story.

D'Agostino RB Sr.

N Engl J Med. 2011 Jul 14;365(2):e2. doi: 10.1056/NEJMp1106984. Epub 2011 Jun 27. No abstract available.

16.

Avastin, ODAC, and the FDA: are we drafting the right players?

Burstein HJ.

J Natl Compr Canc Netw. 2010 Aug;8(8):833-4. No abstract available.

PMID:
20870630
17.

Bevacizumab in ovarian cancer.

Mountzios G, Pentheroudakis G.

N Engl J Med. 2012 Mar 29;366(13):1257; author reply 1258. doi: 10.1056/NEJMc1201044#SA3. No abstract available.

PMID:
22455430
18.

Bevacizumab in ovarian cancer.

Copur MS, Obermiller AM, Ramaekers R.

N Engl J Med. 2012 Mar 29;366(13):1256-7; author reply 1257-8. doi: 10.1056/NEJMc1201044#SA2. No abstract available.

PMID:
22455429
19.

Bevacizumab in ovarian cancer.

Korn EL, Freidlin B, Abrams JS.

N Engl J Med. 2012 Mar 29;366(13):1256; author reply 1257-8. doi: 10.1056/NEJMc1201044#SA1. No abstract available.

PMID:
22455428
20.

The avastin story.

Sekeres MA.

N Engl J Med. 2011 Oct 13;365(15):1454-5. doi: 10.1056/NEJMc1109550. No abstract available.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk